dc.contributor.author |
Badr K. |
dc.contributor.author |
Wainwright C.L. |
dc.contributor.editor |
|
dc.date |
Apr-2004 |
dc.date.accessioned |
2017-10-05T15:48:05Z |
dc.date.available |
2017-10-05T15:48:05Z |
dc.date.issued |
2004 |
dc.identifier |
10.1016/j.coph.2004.01.004 |
dc.identifier.isbn |
|
dc.identifier.issn |
14714892 |
dc.identifier.uri |
http://hdl.handle.net/10938/18649 |
dc.description.abstract |
[No abstract available] |
dc.format.extent |
|
dc.format.extent |
Pages: (107-109) |
dc.language |
English |
dc.publisher |
OXFORD |
dc.relation.ispartof |
Publication Name: Current Opinion in Pharmacology; Publication Year: 2004; Volume: 4; no. 2; Pages: (107-109); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Inflammation in the cardiovascular system: Here, there and everywhere |
dc.type |
Editorial |
dc.contributor.affiliation |
Badr, K., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation |
Wainwright, C.L., School of Pharmacy, The Robert Gordon University, Schoolhill, Aberdeen AB10 1FR, United Kingdom |
dc.contributor.authorAddress |
Badr, K.; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon; email: kbadr@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Office of the VP for Medical Affairs; |
dc.contributor.authorDepartment |
Office of the VP for Medical Affairs |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
kbadr@aub.edu.lb; c.wainwright@rgu.ac.uk |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Badr, K |
dc.contributor.authorInitials |
Wainwright, CL |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Badr, K (reprint author), Amer Univ Beirut, Dept Internal Med and Physiol, Beirut, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
|
dc.description.citedCount |
5 |
dc.description.citedTotWOSCount |
13 |
dc.description.citedWOSCount |
5 |
dc.format.extentCount |
3 |
dc.identifier.articleNo |
|
dc.identifier.coden |
COPUB |
dc.identifier.pubmedID |
15063352 |
dc.identifier.scopusID |
1842610719 |
dc.identifier.url |
|
dc.publisher.address |
THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Curr. Opin. Pharmacol. |
dc.relation.ispartOfIssue |
2 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Current Opinion in Pharmacology |
dc.relation.ispartofPubTitleAbbr |
Curr. Opin. Pharmacol. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
4 |
dc.source.ID |
WOS:000220780500001 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
|
dc.subject.otherChemCAS |
C reactive protein, 9007-41-4 |
dc.subject.otherChemCAS |
caspase 3, 169592-56-7 |
dc.subject.otherChemCAS |
cyclophosphamide, 50-18-0 |
dc.subject.otherChemCAS |
endothelial nitric oxide synthase, 503473-02-7 |
dc.subject.otherChemCAS |
gelatinase A, 146480-35-5 |
dc.subject.otherChemCAS |
interstitial collagenase, 9001-12-1 |
dc.subject.otherChemCAS |
methotrexate, 15475-56-6, 59-05-2, 7413-34-5 |
dc.subject.otherChemCAS |
mycophenolic acid 2 morpholinoethyl ester, 116680-01-4, 128794-94-5 |
dc.subject.otherChemCAS |
rituximab, 174722-31-7 |
dc.subject.otherChemCAS |
tumor necrosis factor alpha converting enzyme, 151769-16-3 |
dc.subject.otherChemCAS |
xanthine oxidase, 9002-17-9 |
dc.subject.otherChemCAS |
Inflammation Mediators |
dc.subject.otherIndex |
alpha interferon |
dc.subject.otherIndex |
antiinflammatory agent |
dc.subject.otherIndex |
antisense oligonucleotide |
dc.subject.otherIndex |
C reactive protein |
dc.subject.otherIndex |
caspase 3 |
dc.subject.otherIndex |
cyclooxygenase 2 |
dc.subject.otherIndex |
cyclooxygenase 2 inhibitor |
dc.subject.otherIndex |
cyclophosphamide |
dc.subject.otherIndex |
endothelial nitric oxide synthase |
dc.subject.otherIndex |
gelatinase A |
dc.subject.otherIndex |
icosanoid |
dc.subject.otherIndex |
immunoglobulin enhancer binding protein |
dc.subject.otherIndex |
interleukin 6 |
dc.subject.otherIndex |
interstitial collagenase |
dc.subject.otherIndex |
low density lipoprotein |
dc.subject.otherIndex |
matrix metalloproteinase inhibitor |
dc.subject.otherIndex |
methotrexate |
dc.subject.otherIndex |
mitogen activated protein kinase p38 |
dc.subject.otherIndex |
Myc protein |
dc.subject.otherIndex |
mycophenolic acid 2 morpholinoethyl ester |
dc.subject.otherIndex |
myeloperoxidase |
dc.subject.otherIndex |
oxidized low density lipoprotein |
dc.subject.otherIndex |
pregnancy associated protein |
dc.subject.otherIndex |
reactive oxygen metabolite |
dc.subject.otherIndex |
rituximab |
dc.subject.otherIndex |
somatomedin |
dc.subject.otherIndex |
tumor necrosis factor alpha converting enzyme |
dc.subject.otherIndex |
tumor necrosis factor alpha converting enzyme inhibitor |
dc.subject.otherIndex |
unindexed drug |
dc.subject.otherIndex |
xanthine oxidase |
dc.subject.otherIndex |
acute heart failure |
dc.subject.otherIndex |
antiinflammatory activity |
dc.subject.otherIndex |
atherogenesis |
dc.subject.otherIndex |
atherosclerosis |
dc.subject.otherIndex |
atherosclerotic plaque |
dc.subject.otherIndex |
Behcet disease |
dc.subject.otherIndex |
cardiovascular inflammation |
dc.subject.otherIndex |
cardiovascular risk |
dc.subject.otherIndex |
clinical trial |
dc.subject.otherIndex |
congestive heart failure |
dc.subject.otherIndex |
drug efficacy |
dc.subject.otherIndex |
drug selectivity |
dc.subject.otherIndex |
drug targeting |
dc.subject.otherIndex |
editorial |
dc.subject.otherIndex |
enzyme activation |
dc.subject.otherIndex |
enzyme inhibition |
dc.subject.otherIndex |
gene mapping |
dc.subject.otherIndex |
giant cell arteritis |
dc.subject.otherIndex |
hepatorenal syndrome |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
immunopathogenesis |
dc.subject.otherIndex |
inflammatory cell |
dc.subject.otherIndex |
nonhuman |
dc.subject.otherIndex |
oxidative stress |
dc.subject.otherIndex |
pathophysiology |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
reperfusion injury |
dc.subject.otherIndex |
risk factor |
dc.subject.otherIndex |
systemic vasculitis |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Inflammation Mediators |
dc.subject.otherIndex |
Myocarditis |
dc.subject.otherIndex |
Vasculitis |
dc.subject.otherKeywordPlus |
|
dc.subject.otherWOS |
Pharmacology and Pharmacy |